From the Book - Thirty-sixth edition.
Individual drug monographs
Appendixes: A. Selected new drugs:abametapir ; aducanumab-avwa ; afamelanotide ; anifrolumab-fnia ; asciminib ; atogepant ; avacopan ; avapritinib ; belumosudil ; belzutifan ; bempedoic acid ; brolucizumab-dbll ; difelikefalin ; dostarlimab-gxly - eculizumab ; efavirenz/emtricitabine/tenofovir ; elapegademase-ivir ; elbasvir/grazoprevir ; elexacaftor/tezacaftor/ivacaftor and ivacaftor ; emtricitabine/rilpivirine/tenofovir alafenamide ; enalapril/hydrochlorothiazide ; ephedrine ; factor IX, complex ; factor IX, human ; factor IX, recombinant ; finerenone ; fluocinolone ; fluocinonide ; lonapegsomatropin-tcgd ; loncastuximab tesirine-lpyl ; maribavir ; mobocertinib ; odevixibat ; ropeginterferon alfa-2b ; tisotumab vedotin-tfv ; vosoritide
B. Ophthalmic, nasal, topical, and otic products
D. Recent FDA drug approvals.
